Chronic hepatitis B therapeutics market to reach $3.2bn across 7MM in 2034
By 2034, more than 65% of the CHB market will be attributed to sales from specific functional cure drugs.
By 2034, more than 65% of the CHB market will be attributed to sales from specific functional cure drugs.